Skip to main content

4 Result(s)

within M. Kuoppamäki Remove this filter

and

  1. No Access

    Article

    L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates

    Most patients with Parkinson’s disease (PD) develop dyskinesia and other motor complications after prolonged L-dopa use. We now report on the relationship between L-dopa dose and the duration and severity of d...

    M. Kuoppamäki, G. Al-Barghouthy, M. J. Jackson… in Journal of Neural Transmission (2007)

  2. No Access

    Article

    Striatal presynaptic dopamine function in type 1 alcoholics measured with positron emission tomography

    Recent in vivo studies have shown low dopamine D2 receptor and dopamine transporter densities among late onset (type 1) alcoholics. We have now studied 6-[18F]-FDOPA (FDOPA) uptake in 10 type 1 alcoholics and eig...

    J Tiihonen, H Vilkman, P Räsänen, O-P Ryynänen, H Hakko, J Bergman… in Molecular Psychiatry (1998)

  3. No Access

    Article

    Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography

    The modulating effect of serotonergic drugs on the striatal dopamine neurotransmission has remained controversial, and there are no published data on serotonin-dopamine interaction obtained from living human b...

    J. Tiihonen, M. Kuoppamäki, E. Syvälahti, K. Någren, E. Eronen… in Psychopharmacology (1996)

  4. No Access

    Article

    Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2C receptor

    Interactions of the selective serotonin reuptake inhibitors (SSRIs) citalopram, fluoxetine and its main metabolite norfluoxetine, and the tricyclic anti-depressant (TCA) imipramine with the rat serotonin 5-HT2C r...

    E. -P. Pälvimäki, H. Majasuo, A. Laakso, M. Kuoppamäki, E. Syvälahti… in Psychopharmacology (1996)